| Trial ID: | L4818 |
| Source ID: | NCT00495014
|
| Associated Drug: |
Gsk376501
|
| Title: |
Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: GSK376501|DRUG: Placebo
|
| Outcome Measures: |
Primary: Adverse reactions and changes in laboratory values, vital signs, and/or ECGs following each dose, following each dose | Secondary: Blood levels of GSK376501 following 1 day (Part A) or 14 days (Part B) of dosing, following 1 day (Part A) or 14 days (Part B) of dosing|GSK376501 plasma levels to derive pharmacokinetic parameters following single and repeat doses for 14 days|Standard markers that may serve as possible surrogates of volume expansions with GSK376501.|Body weight following 14 days of repeat dosing with GSK376501.
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
70
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2007-06
|
| Completion Date: |
2007-12
|
| Results First Posted: |
|
| Last Update Posted: |
2010-10-15
|
| Locations: |
GSK Investigational Site, Evansville, Indiana, 47714, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00495014
|
